Table 2 Comparison of the clinical features between the clusters derived from metabolic profiling of the EBC
From: Exhaled breath condensate metabolome clusters for endotype discovery in asthma
Variable | Cluster 1 (n = 41) | Cluster 2 (n = 11) | Cluster 3 (n = 9) | p value |
|---|---|---|---|---|
Age (months) | 113.98 ± 34.53 | 123.45 ± 39.61 | 123.44 ± 48.95 | 0.71 |
Male | 9 (21.95%) | 11 (100%) | 4 (44.44%) | 0.053 |
BMI | 16.09 ± 3.22 | 15.08 ± 3.94 | 15.70 ± 1.91 | 0.66 |
Age of onset (months) | 33.74 ± 33.84 | 51.09 ± 47.33 | 28.67 ± 22.97 | 0.41 |
Atopy present* | 19 (57.57%) | 6 (75%) | 5 (62.5%) | 0.66 |
Both maternal and paternal family history present | 25 (60.09%) | 8 (72.73%) | 9 (100%) | 0.06 |
FEV1% predicted | 89.44 ± 17.13 | 81.36 ± 16.24 | 84.67 ± 15.12 | 0.34 |
TLC (× 103 cells/μL) | 9.28 ± 3.33 | 8.79 ± 1.60 | 9.42 ± 2.24 | 0.70 |
% Eosinophils | 3.69 ± 2.52 | 6.54 ± 12.45 | 2.56 ± 0.53 | 0.024 |
% Polymorphs | 55.80 ± 13.4 | 54.64 ± 7.53 | 63.89 ± 6.15 | 0.01 |
ESR mm/h | 20.07 ± 9.25 | 17.82 ± 4.04 | 21.22 ± 8.90 | 0.39 |
FeNO (ppb) | 18.73 ± 12.23 | 23.36 ± 14.12 | 27.67 ± 29.16 | 0.47 |
Corticosteroid use | 33 (80.49%) | 7 (63.36%) | 6 (66.67%) | 0.41 |
Exacerbation ratio | 0.15 ± 0.17 | 0.31 ± 0.24 | 0.27 ± 0.16 | 0.018 |